



ALK Positive Negative 2 in 1 FFPE Block Reference Standard

CBPN0022

I. Description

The incidence of anaplastic lymphoma kinase (ALK) gene fusion in non-small cell lung cancer in my country is about 5.6%, of which the incidence in adenocarcinoma is 6.6%~9.6%. In recent years, great breakthroughs have been made in the research and development and clinical application of ALK inhibitors, including first-generation (such as crizotinib), second-generation (such as alectinib, ceritinib, brigatinib) and even third-generation ALK inhibitors (Lorlatinib), which can significantly improve the objective response rate and prolong progression-free survival (PFS) of patients with ALK-positive advanced non-small cell lung cancer. It is of great clinical significance to select accurate, rapid and appropriate ALK detection methods to screen the target population suitable for ALK inhibitors.

II. General information


Name	ALK Positive Negative 2 in 1 FFPE Block Reference Standard
Cat. No.	CBPN0022
Format	FFPE Block
Size	4mm/block
Intended Use	Research Use Only
Buffer	Tris-EDTA
Storage Conditions	-25~-15°C
Expiry	36 months from the date of manufacture

III. Technical Data

Cell number Subject to actual situation

Paraffin block
thickness 4mm

Example



IV. IHC staining results

